Emergent BioSolutions to Unveil its Expanded Center for Innovation in Advanced Development and Manufacturing Supported through Public-Private Partnership with BARDA
Emergent BioSolutions to Unveil its Expanded Center for Innovation in Advanced Development and Manufacturing Supported through Public-Private Partnership with BARDA
ADVISORY,
| WHO: | Emergent BioSolutions Inc. (NYSE:EBS) |
| WHAT: | Ribbon-cutting and tour of expanded Emergent BioSolutions’ Center for |
| Innovation in Advancement Development and Manufacturing (CIADM), | |
| featuring speakers: | |
| Daniel J. Abdun-Nabi | |
| President & Chief Executive Officer, Emergent BioSolutions | |
| Rick A. Bright, Ph.D. | |
| Director, Biomedical Advanced Research and Development Authority (BARDA) | |
| Deputy Assistant Secretary, Office of the Assistant Secretary for Preparedness | |
| and Response at the U.S. Department of Health and Human Services (HHS) | |
| William H. Cole | |
| President & CEO, Baltimore Development Corporation | |
| Secretary Mike Gill | |
| Department of Commerce, State of Maryland | |
| WHY: | Five years ago, Emergent and BARDA entered into a public-private partnership |
| to establish a CIADM intended to develop and manufacture medical | |
| countermeasures to protect the public in health emergencies. | |
| This Wednesday, Emergent will unveil its newly expanded Baltimore CIADM | |
| facility – one of only three HHS-designated Centers in the United States. The | |
| 112,000-square-foot facility, comprised of laboratory, manufacturing and office | |
| space, offers flexible manufacturing of drug substance from microbial, cell | |
| culture, or viral production platforms. Its capabilities for advanced | |
| development and manufacturing of medical countermeasures were designed to | |
| help address the U.S. government’s national security and public health needs. | |
| The facility is equipped with disposable manufacturing technology to enable | |
| Emergent to meet the government’s domestic preparedness priorities and | |
| needs on a cost-effective, reliable and sustainable basis. | |
| Since its inception, the Emergent CIADM has been awarded four task orders by | |
| BARDA to develop Ebola and Marburg therapeutics and a Zika vaccine. | |
| Emergent has also successfully manufactured some of its product candidates | |
| at the CIADM and an Ebola vaccine candidate as part of a third-party | |
| collaboration. | |
| WHERE: | Emergent BioSolutions Bayview Campus |
| 5901 East Lombard St. | |
| Baltimore, MD 21224 | |
| WHEN: | Wednesday, May 10, 2017 |
| 9 a.m. to 11 a.m. |
About
Media Contact:Lynn Kieffer Vice President, Corporate Communications 240-631-3391 kiefferl@ebsi.com